What Is Wrong with Orphan Drug Policies?
-
Patents Against People: How Drug Companies Price Patients out of Survival – Courtesy (Dissent)
Pharma Live, , Intellectual Property Rights, 0
As our television screens toggle between pundits squabbling over Obamacare’s insurance rules and ads for erectile dysfunction remedies, another...
-
Court Denies Generic Drug Manufacturer’s Motion to Dismiss Hatch-Waxman Patent Infringement Action on Jurisdiction Grounds
Pharma Live, , Intellectual Property Rights, 0
the United States District Court for the Southern District of Indiana joined the District of Delaware and Eastern District...
-
The Remicade Biosimilar Patent Dispute
Pharma Live, , Intellectual Property Rights, 0
POSTED BY COURTENAY C. BRINCKERHOFF ON 10 MARCH 2015POSTED IN BIOSIMILARSWhile Sandoz has grabbed the biosimilar headlines for being the first company to have a...
-
FDA To Give 5 Year NCE Exclusivity To Combinations – Courtesy (Pharma Patents)
Pharma Live, , Intellectual Property Rights, 0
POSTED BY COURTENAY C. BRINCKERHOFF ON 26 FEBRUARY 2014POSTED IN FDAIn a Federal Register Notice dated February 24, 2014, the U.S. FDA announced a...
-
FDA Releases Draft Guidance on Biosimilars
Pharma Live, , Intellectual Property Rights, 0
POSTED BY COURTENAY C. BRINCKERHOFF ON 9 FEBRUARY 2012POSTED IN BIOSIMILARSOn February 9, 2012, the FDA issued long-awaited (draft) guidance documents on...
-
The new drugs war – Courtesy (The Economists)
Pharma Live, , Intellectual Property Rights, 0
OF ALL the goods and services traded in the market economy, pharmaceuticals are perhaps the most contentious. Though produced...
-
California Supreme Court Scrutinizes Reverse Payment ANDA Settlements – Courtesy (Pharma Patents)
Pharma Live, , Intellectual Property Rights, 0
POSTED BY COURTENAY C. BRINCKERHOFF ON 12 MAY 2015POSTED IN ANTITRUSTIn In Re Cipro Cases I & II, the California Supreme Court laid...
-
It’s not just big pharma that wants to see IPR reform in US patent legislation – By Richard Lloyd
Pharma Live, , Intellectual Property Rights, 0
For over an hour yesterday, as the Senate Judiciary Committee hearing on the recently introduced PATENT Act unfolded, it seemed like we were...
![](https://ml7mn4k5dnn0.i.optimole.com/w:289/h:289/q:eco/f:best/https://interactivepharm.com/wp-content/uploads/2022/08/Show-your.jpg)